Multiple myeloma research is rapidly evolving with bispecific antibodies, CAR-T cell therapy, and next-generation maintenance strategies.
PATHFINDER 2, a prospective, interventional cohort study of 35,878 adults aged 50 and older with no clinical suspicion of cancer, evaluated the performance and safety of a blood-based multi-cancer early detection (MCED) test that analyzes cell-free DNA methylation patterns to detect a shared cancer signal and predict its tissue of origin.
A multicentre, externally controlled phase 2 trial (OPTIMUM/MUKnine) across 22 UK centres tested intensified induction with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone, followed by autologous stem-cell transplantation, extended consolidation, and daratumumab-lenalidomide maintenance in 107 patients with newly diagnosed high-risk multiple myeloma, compared against a molecularly matched external control cohort of 120 patients from the Myeloma XI trial.
A registry-based analysis of 11,681 US interventional cancer trials registered on ClinicalTrials.gov between 2008 and 2024 found that industry sponsors now outnumber federal sponsors nearly 5 to 1 (4.53-to-1 overall), with the ratio widening from 2.72-to-1 in 2008–2012 to 6.44-to-1 in 2019–2024.
Randomized phase 3 comparison, from the maintenance ("R2") randomization of the ECOG-ACRIN ENDURANCE (E1A11) trial, of indefinite-duration versus fixed 2-year lenalidomide maintenance in 516 standard-risk multiple myeloma patients who did not undergo up-front autologous stem-cell transplantation.